Rhonda Farnum Sells 4,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Theravance Biopharma Price Performance

Shares of TBPH opened at $9.57 on Friday. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $11.71. The firm has a 50 day simple moving average of $8.36 and a two-hundred day simple moving average of $8.69. The company has a market cap of $468.16 million, a P/E ratio of -9.48 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative return on equity of 24.23% and a negative net margin of 78.18%. During the same quarter last year, the firm posted ($0.17) earnings per share. On average, analysts expect that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Theravance Biopharma by 41.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock worth $5,005,000 after purchasing an additional 163,951 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Theravance Biopharma by 38.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after buying an additional 91,679 shares during the period. BNP Paribas Financial Markets grew its position in shares of Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after buying an additional 143,781 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after buying an additional 135,426 shares during the period. Finally, GSA Capital Partners LLP increased its stake in shares of Theravance Biopharma by 12.6% in the third quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock valued at $1,852,000 after buying an additional 25,691 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on TBPH. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Finally, TD Cowen decreased their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.